Clinical Neuropsychologist最新文献

Objective: Suicide is a leading cause of death globally. Clinical neuropsychologists may see patients at increased risk of suicide who may have had no prior engagement with another mental health provider. Even if their role is limited to a single encounter, neuropsychologists can still incorporate specific practices (e.g. into their interview appointment) that help reduce a patient's suicide risk. Method: This review aims to highlight current best practices for suicide risk assessment and management, emphasizing the crucial role neuropsychologists can play in suicide prevention. Conclusions: Neuropsychologists' involvement in healthcare systems positions them to implement effective suicide prevention strategies, including the Zero Suicide (ZS) framework. The ZS framework is a systematic approach to improve suicide prevention through the implementation of evidence- based strategies including specific strategies to use when working with patients (i.e. identify, engage, treat, and transition). Effective screening tools for suicidal thoughts and behaviors include the Columbia-Suicide Severity Rating Scale (C-SSRS) and the Ask Suicide-Screening Questions (ASQ) Toolkit. Brief interventions that can be incorporated into an assessment appointment, such as safety planning and means safety interventions, demonstrate significant reductions in suicidal behavior and improved engagement with mental health treatment. Neuropsychologists can refer patients to evidence-based treatments that directly target suicide risk and support at-risk patients through transitions in care by employing strategies like Caring Contacts and structured follow-up calls. By integrating these best practices and engaging in continuous education, neuropsychologists can significantly contribute to reducing suicide risk among their patients.

Background: In the field of clinical neuropsychology, researchers and clinicians often use predefined criteria to determine whether there are indications of cognitive impairment. However, corrections and expected false-positive rates are typically available only for uncorrelated tests and simple consensus criteria. Objective: To present an easy-to-use and freely available online tool as a solution for scenarios involving correlated tests and composite consensus criteria, as frequently encountered in clinical neuropsychological research and practice. Method: Our tool employs Monte Carlo simulations to account for the number of participants, thus addressing the uncertainty in estimating false positive rates with small samples. We demonstrate the tool's utility through an example involving cognitive impairment assessment in cancer patients after chemotherapy. Results: The tool reveals considerable uncertainty in false positive rates, especially with small sample sizes, where rates may be higher than traditionally assumed. We found that correlations between tests affect impairment rates differently depending on whether single or multiple test criteria are used. For single-test criteria, lower correlations are associated with more false positives, while for multiple-test criteria, lower correlations lead to fewer false positives. Conclusions: This innovative tool enables more accurate estimation of false positive rates in various neuropsychological conditions. By providing a user-friendly interface and accounting for real-world complexities such as test correlations and composite criteria, our tool empowers clinicians and researchers to:Make informed decisions when interpreting neuropsychological test results.Design more robust research protocols for cognitive impairment studies.Better understand the implications of sample size on false positive rates.

Objective: Neurobehavioral disturbances often follow acquired brain injuries. Patients and family members may perceive these anomalies differently, and these discrepancies are difficult to interpret due to methodological constraints. We explored the differing perceptions of behavioral alterations in patients with severe acquired brain injury (sABI) and their caregivers using the Latent Difference Score (LDS) analysis. We also examined the relation between the behavioral ratings and demographic, injury, and functional variables. Method: Data from 154 patients with sABI in the post-acute phase and their caregivers were retrospectively analyzed. The BIRT Personality Questionnaire was used to assess behavioral disorders. Results: We examined four subscales: Lack of Motivation (LoM), Lack of Emotion Regulation (LoER), Negative Emotionality/Reactivity (NE), and Lack of Social Skills (LoSS). Patients generally tended to underestimate their problematic behaviors compared to their family members. Sex predicted patient/caregiver discrepancies in the LoM and LoER subscales, with male patients perceiving themselves as higher functioning than female patients. The scale measuring physical disability was not associated with patient/caregiver discrepancies, except for LoER, with family members' judgments of greater severity correlated with lower functional scores. Conclusions: Notable gaps emerged between subjective and family perceptions, particularly in motivation and social skills. The discrepancies were associated with sex differences. LDS is a promising tool for examining patient/caregiver discrepancies in patients with ABI.

Objective: The analysis of risk of bias in systematic reviews (SR) and meta-analyses (MA) is a fundamental task to ensure the correct synthesis of results. To carry out this task, specific tools must be used for each research design of the studies analyzed. The choice of an appropriate tool is currently a challenge for researchers developing SR and MA in the area of symptom and performance validity because the research designs used have been created specifically for this field. Although these designs can be integrated within the classic classifications, they present a number of particular characteristics that are not reflected in any of the current risk of bias analysis tools. The aim of this study is to design a checklist specifically for systematic review/meta-analysis focused on validity tests. Methods: The checklist was developed through objective review of the existing evidence, development of checklist items, and refinement by external feedback and performance analysis. Results: The checklist is composed of four sections: Clinical comparison group selection, sources of bias in either simulation or criterion group designs, and overall assessment of the study. Inter-rater reliability was assessed with a sample of 20 studies, resulting in good to excellent intraclass correlation coefficients for most items. Conclusions: The checklist seeks to fill an important gap in the literature by serving as an assessment tool that improves the reliability of evidence synthesis in symptom and performance validity studies. This instrument facilitates the development of SR and MA that meet international standards, improving methodological rigor and reliability in the forensic setting.

Objective: Despite significant progress in understanding the factors influencing cognitive function in Parkinson's disease (PD), there is a notable gap in data representation for the Latinx population. This study aims to evaluate the contributors to and disparities in cognitive performance among Latinx patients with PD. Methods: A retrospective analysis was conducted based on cross-sectional data encompassing demographic, environmental, motor, and non-motor disease characteristics from the Latin American Research Consortium on the Genetics of PD (LARGE-PD) and the Parkinson's Progression Markers Initiative (PPMI) cohorts. Linear regression multivariable models were applied to identify variables affecting Montreal Cognitive Assessment (MoCA) scores, accounting for age, sex, and years of education. Results: The analysis comprised of 3,054 PD patients (2,041 from LARGE-PD and 1,013 from PPMI) and 1,303 Latinx-controls. Latinx-PD patients (mean age 63.0 ± 11.8, 56.8% male) exhibited a significantly lower average MoCA score (p < .001) compared to white Non-Hispanic PD patients from PPMI (mean age 67.5 ± 9.9, 61.7% male). This difference persisted when comparing the Latinx-PD to the Latinx-controls (mean age 58.7 ± 9.3, 33.2% male; p < .001). Factors significantly associated with better MoCA scores in Latinx-PD included unilateral symptom onset (p = .009), and higher educational attainment (p < .001). Conversely, those associated with worse scores included the use of dopamine agonists (p = .01), previous tobacco use (p = .01), older age (p < .001), and a higher Hoehn and Yahr scale score (p < .001). Conclusions: Latinx-PD patients demonstrated significantly lower cognitive scores compared to their white non-Hispanic PD counterparts and Latinx-controls. These results highlight the importance of interpreting MoCA scores in a nuanced manner within diverse populations.

Objective: Older adults with cognitive impairment are at risk of medication-taking errors. This study assessed the impact of providing medication adherence feedback to cognitively impaired older adults. Methods: Forty participants with mild cognitive impairment or mild dementia had their medication adherence electronically monitored for 8 weeks. They were provided with verbal and visual feedback about their adherence results. Initial participant reactions were elicited using a Motivational Interviewing approach, and self-reported behavior changes were assessed during a follow-up interview. Quantitative analyses assessed relationships among electronically monitored and self-rated adherence, initial reactions to adherence feedback, and subsequently reported medication self-management changes. Thematic analysis determined facilitators and barriers to making self-management changes. Results: Although self-rated adherence was high, electronic monitoring revealed that 20% of the sample had suboptimal adherence (took the recommended dose on <80% of monitored days). Fifty-three percent of the sample reported feeling surprised by their adherence results, and 45% endorsed initial motivation to change self-management behaviors. Motivated participants demonstrated worse electronically monitored adherence than unmotivated peers, and those who were surprised by their medication-taking errors expressed greater initial motivation to change. At follow-up, 50% reported having made changes, and 82.4% of them indicated that this study played a role. Facilitators of making changes included awareness of medication-taking errors and cognitive impairment, whereas barriers included lack of perceived difficulty/need. Conclusions: Adherence monitoring with feedback is feasible and impactful in cognitively impaired older adults. Increasing awareness of medication-taking errors fosters motivation to improve medication self-management and results in participant-reported behavior change.

Objective: Obstructive sleep apnea (OSA) has been associated with structural and functional brain changes and cognitive impairment in sleep clinic samples. Persons with traumatic brain injury (TBI) are at increased risk of OSA compared to community samples, and many experience chronic cognitive disability. However, the impact of OSA on cognitive outcome after TBI is unknown. The purpose of this study was to examine the relationship between polysomnographic sleep parameters on neuropsychological performance 2 years following TBI. We hypothesized that oxygen desaturation, sleep fragmentation, and sleep depth would predict neuropsychological performance. Method: Participants (N = 123) were persons with moderate-to-severe TBI who underwent Type 1 Polysomnography during acute neurorehabilitation. At 2 years post-TBI, participants completed telephone-based neuropsychological testing (the Brief Test of Adult Cognition by Telephone). General linear models were fit to investigate the relationship between sleep parameters and neuropsychological performance, controlling for demographics and posttraumatic amnesia. Results: When controlling for demographics, injury characteristics, and other sleep parameters, greater percent of Stage 1 sleep time predicted poorer cognitive performance (Overall BTACT composite, p = 0.0078, η_p2 = 6.6%; Verbal Memory composite, p = 0.0407, η_p2 = 3.9%; Executive Function composite, p = 0.0215, η_p2 = 4.9%). Oxygen desaturation, cortical arousals, Stage 3 sleep, and the obstructive apnea-hypopnea index were not significantly associated with cognitive outcome. Conclusions: Reduced sleep depth was associated with cognitive outcome in persons with TBI; these findings require replication. Future research should examine whether improving sleep (e.g. increasing deep sleep) during acute recovery can improve cognitive recovery following TBI.

Objective: People with functional seizures (FS) have frequent and disabling cognitive dysfunction and mental health symptoms, with low quality of life. However, interrelationships among these constructs are poorly understood. In this meta-analysis, we examined associations between objective (i.e. performance-based) cognitive testing and self-reported (i) mental health, (ii) cognition, and (iii) quality of life in FS. Method: We searched MEDLINE, Embase, PsycINFO, and Web of Science, with the final search on June 10, 2024. Inclusion criteria were studies documenting relationships between objective cognitive test scores and self-reported (i.e. subjective) mental health, cognition, and/or quality of life in adults with FS. Exclusion criteria were mixed FS/epilepsy samples. A modified Newcastle-Ottawa Scale evaluated risk of bias. This project is registered as CRD42023392385 in PROSPERO. Results: Initially, 4,054 unique reports were identified, with the final sample including 24 articles of 1,173 people with FS. Mean age was 35.9 (SD = 3.9), mean education was 12.6 (SD = 1.3), and proportion of women was 73.9%. Risk of bias was moderate, due in part to inconsistent reporting of confounding demographic variables. Significant relationships were found between global objective cognition and global self-reported mental health (k = 21, Z = -0.23 [0.04], 95% CI = -0.30, -0.16), depression (k = 11, Z = -0.13 [0.05], 95% CI = -0.21, -0.04), cognition (k = 5, Z = -0.16 [0.05], 95% CI = -0.26, -0.06), and quality of life (k = 5, Z = -0.17 [0.05], 95% CI = -0.24, -0.10). Exploratory analyses showed associations between select cognitive and mental health constructs. Conclusions: Objective cognition is reliably associated with self-reported mental health, cognition, and quality of life in people with FS. Scientific and clinical implications are discussed.

Objective: Few performance validity tests exist for youth undergoing baseline testing for the management of sport-related concussion. This study provides an initial validation of a reliable span calculation from the Wechsler Intelligence Scale for Children-Fourth Edition Letter-Number Sequencing (LNS) subtest as a performance validity indicator for youth baseline testing (Reliable Letter-Number Span; RLNS). Method: Youth athletes (n = 173) underwent baseline concussion testing for the management of sport-related concussion. We classified participants as valid (n = 153) or invalid performance (n = 20) based on several well-established performance validity tests. We calculated RLNS by summing the spans of alphanumeric characters across two items within the Letter-Number Sequencing subtest, similar to the Reliable Digit Span. To better determine the utility of RLNS, we also examined other novel reliable span metrics and established summary scores from the Letter-Number Sequencing as potential validity indicators. Results: Analyses revealed excellent classification accuracy for RLNS, with an area under the curve of .88 (95% CI [.81, .96]). The optimal cutoff for RLNS (≤6) yielded .55 sensitivity and .95 specificity. Results showed similar but slightly lower classification accuracy statistics (areas under the curve of .77-.86) for the other LNS validity indicators. Conclusion: Initial findings support the criterion validity of RLNS as an embedded validity indicator. This measure is among the few extant performance validity tests that may be appropriate for youth baseline concussion testing. RLNS may also be appropriate for other types of pediatric evaluations. However, additional support is necessary before neuropsychologists can use RLNS clinically.